{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:21:17Z","timestamp":1778170877443,"version":"3.51.4"},"reference-count":8,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Anti\u2010tumour necrosis factor\u2010\u03b1 (TNF\u03b1) agents are effective in diseases including Crohn's disease but may cause cytopenias. The mechanisms involved in anti\u2010TNF\u03b1 agent\u2010induced thrombocytopenia are scarce. We report a 73\u2010year\u2010old male with Crohn's disease for which he currently used adalimumab, an anti\u2010TNF\u03b1 agent. He had received mesalazine and infliximab before the treatment of adalimumab. No comorbidities were present. Routine laboratory tests revealed a deep thrombocytopenia (thrombocytes 24\u00a0\u00d7\u00a010<jats:sup>9<\/jats:sup>\/L), after which adalimumab was discontinued. Bleeding symptoms included cutaneous haematomas and mild epistaxis. Direct monoclonal antibody\u2010specific immobilization of platelet antigens revealed autoantibodies specific to glycoprotein IIb\/IIIa and glycoprotein V platelet receptors. There was no bone marrow suppression. Other causes of the thrombocytopenia were ruled out. The platelet count normalized after adalimumab discontinuation. No further interventions were required. Monitoring thrombocyte levels after initiating anti\u2010TNF\u03b1 agents is recommended, which could lead to prevention of this potentially fatal phenomenon.<\/jats:p>","DOI":"10.1111\/bcp.14778","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T10:30:32Z","timestamp":1613644232000},"page":"3619-3621","source":"Crossref","is-referenced-by-count":7,"title":["Adalimumab\u2010induced platelet antibodies resulting in severe thrombocytopenia"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6381-9908","authenticated-orcid":false,"given":"Henk\u2010Jan","family":"Boiten","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-0044","authenticated-orcid":false,"given":"Sufia","family":"Amini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Haga Hospital  The Hague The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5308-1735","authenticated-orcid":false,"given":"Frank H. J.","family":"Wolfhagen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Albert Schweitzer Hospital  Dordrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0746-7039","authenticated-orcid":false,"given":"Peter E.","family":"Westerweel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Albert Schweitzer Hospital  Dordrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel204"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14681"},{"issue":"3","key":"e_1_2_8_5_1","first-page":"280","article-title":"Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor\u2010a inhibitors","volume":"10","author":"Chen M","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00033"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.04.001"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.123547"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03360.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14778","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14778","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:44:53Z","timestamp":1693345493000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/bcp.14778"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14778","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}